A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer.
Cuc Thi Thu NguyenFabio PetrelliStefania ScuriBinh Thanh NguyenIolanda GrappasonniPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2019)
Most of these high-quality studies suggested that erlotinib was cost-effective in the first-line treatment of advanced NSCLC.